SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending due to a significant sell-off following a disappointing Q4 earnings report and weak FY26 guidance, which has led to analyst downgrades and intense debate among investors; bears cite high debt and declining U.S. sales, while bulls see an overreaction, highlighting the attractive dividend yield, international growth, and potential for a short squeeze or private equity buyout.

Atomera, Inc. engages in the development, commercialization, and licensing of proprietary processes and technologies for the semiconductor industry. It developed Mears Silicon Technology, which increases performance and power efficiency in semiconductor transistors. The company was founded by Robert Mears on November 26, 2001 and is headquartered in Los Gatos, CA.

Atomera Inc

Atomera (ATOM) is trending with explosive trading volume and active community discussion after its Q4 earnings call signaled significant technical breakthroughs in Gate-All-Around (GAA) and wafer-based MST applications, fueling management's confidence in securing commercial licensing deals despite persistent investor skepticism.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is gaining significant attention following recent defense contracts, including an $11.5 million production deal and its qualification as the first U.S. Army additive manufacturing vendor for ground vehicle systems. The community is actively debating its critical role in the rapidly expanding defense and aerospace 3D printing sector, anticipating further major partnerships and potential for a short squeeze despite observed price volatility.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

The quantum technology firm Infleqtion ($INFQ) is generating significant conversation following its NYSE debut, with the community actively discussing its neutral-atom technology, defense and NVIDIA partnerships, and perceived undervaluation compared to other quantum stocks, even as some experience brokerage update delays.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM Integrated Shipping Services is in focus after an all-cash acquisition offer from Hapag-Lloyd set a definitive per-share price, leading to widespread discussion on the significant arbitrage opportunity. The community is actively weighing the deal's likelihood given potential regulatory and geopolitical hurdles, alongside speculation about a short squeeze and the status of future dividends during the prolonged closing period.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is currently trending due to a significant market reaction to its latest guidance, fueling widespread buyout speculation. Community discussions are intensely focused on the long-term impact of AI on its game development platform, with competitive offerings like Project Genie adding to the narrative.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending ahead of its earnings report, with community discussion revolving around its strategic acquisitions, including AI-powered Koi Security, and an expanded partnership with Google Cloud to secure AI workloads. While some investors are concerned about valuation and potential dilution, many see the recent sector sell-off as an overreaction, arguing that AI adoption will significantly increase the demand for robust cybersecurity solutions.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is experiencing significant volatility after announcing positive topline results from its AXPAXLI SOL-1 superiority trial for wet AMD; while the drug demonstrated superior vision maintenance and reduced injection burden, the market reacted with a sharp sell-off, prompting intense debate among investors over perceived efficacy differences and the drug's long-term commercial potential versus its convenience benefits and potential as a buyout target.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings is trending after reporting robust earnings and an optimistic outlook, driven by accelerating demand for its optical components in AI and cloud data centers. The community is actively debating its parabolic rise, with proponents seeing it as an indispensable AI infrastructure provider, while detractors warn of an overextended valuation and notable insider selling.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Positive Phase 3 trial results for COMPASS Pathways' COMP360 psilocybin therapy for treatment-resistant depression are driving significant conversation, with the company also accelerating commercialization plans. The community is weighing its potential as a first-to-market FDA-approved psychedelic treatment against concerns about market viability and competitive landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?

BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.

Cytokinetics (CYTK) Expected to Announce Earnings on Tuesday

Cytokinetics (NASDAQ:CYTK) will be releasing its Q4 2025 earnings after the market closes on Tuesday, February 24. (View Earnings Report at...

Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study

Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.

Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 15,000 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 15,000 shares of the stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of...

Andrew Callos Sells 15,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 15,000 shares of the firm's stock in a transaction dated Thursday, February 5th. The shares were sold at an average...

Truist Financial Forecasts Strong Price Appreciation for Cytokinetics (NASDAQ:CYTK) Stock

Truist Financial increased their target price on shares of Cytokinetics from $84.00 to $92.00 and gave the stock a "buy" rating in a report on Tuesday...

Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 886 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 886 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $62.10...

Lisanti Capital Growth LLC Acquires New Position in Cytokinetics, Incorporated $CYTK

Lisanti Capital Growth LLC acquired a new stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with...

Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates

Regeneron (REGN) delivered earnings and revenue surprises of +8.32% and +1.77%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Current Price	$66.63
Prev Close	$66.26
Open	$64.80
Dividend Yield	0.00%
50-Day Moving Average	$63.50
Beta	0.95
Avg. Volume	1.8M
PE Ratio	-10.50

52-Week High	$70.98
52-Week Low	$29.31
Market Capitalization	$8.1B
EPS (Annual)	-$5.26
Price to Book	-15.53
Revenue Per Employee	$37,096.39

CYTK
Cytokinetics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CYTK News

CYTKCytokinetics Inc